Biology, detection, and management of incidental pulmonary nodules: the emerging role of targeted treatments. A review of the current literature and future perspectives.

Lung cancer is the leading cause of cancer-related deaths globally, and early diagnosis and treatment are important for improving prognosis. Pulmonary nodules (PNs) are small pulmonary lesions frequently identified during clinical practice, with incidental detection increasing due to advances in imaging techniques and the expanded use of computed tomography scans for thoracic evaluation. The majority of incidental PNs (IPNs) are benign, however some represent early-stage lung cancer, therefore distinguishing benign from malignant IPNs is key to improving lung cancer outcomes. Current management guidelines differ by nodule type and involve biopsy to determine the malignancy status of the nodule. Here, we review current knowledge on the classification, prevalence, and detection of PNs, as well as the current management and risk stratification of PNs. We outline the role of oncogenic driver mutations in the pathobiology of PNs and assess current literature on targeted treatment of oncogene-driven PNs. Finally, we discuss evidence gaps and areas for future research.